Hospital/Health-System Pharmacy

Editor's Choice

Drug prices can't depend on who's buying

In the prescription drug market, discriminatory pricing is common for independent community pharmacies and their patients. This fall, a Federal District Court in New York will consider a critical case: Drug Mart Pharmacy Corp. et a. v. American Home Products Corp. et al. The outcome of the case may determine whether discriminatory pricing techniques are illegal.

LATEST ARTICLES

Healthcare Reform: Drug Topics readers speak out

With the subject of healthcare reform on the front burner in Washington and across the country, Drug Topics invited members of its Frontline editorial advisory board to share their thoughts. A selection of their responses is presented here.

Practical management of asthma (CE)

More than 22 million patients in the United States are affected by asthma and collectively were admitted for approximately 444,000 hospitalizations in 2006. With appropriate assessment and treatment by patients and healthcare providers, hospitalizations and deaths from asthma exacerbations can be significantly reduced. This article reviews the role of available asthma medications and provides an overview of the NAEPP's recommendations for management of asthma for patients 12 years of age and older.

Integrating Late-Breaking Growth Factor Evidence, Guidelines, and Policy Into Clinical Practice

Metabolic syndrome throughout the life cycle (CE)

Prevalence of metabolic syndrome in adults, as well as the increasing prevalence of pediatric obesity, has spurred research into how the condition may affect children and adolescents. Pharmacists should be able to define insulin resistance and metabolic syndrome in children and adults according to national guidelines, list the risk factors associated with metabolic syndrome in children that may increase their risk as adults, describe the role of lifestyle modification in children and adults with metabolic syndrome, and identify the role of medical and surgical treatment for metabolic syndrome and/or obesity.

Biogeneric drugs and brands: The future market share

When manufacture of biogenerics is a legal reality, brand manufacturers will still retain a strong market share for several years.